TABLE 3.
Antibiotic susceptibilities of clinical P. mirabilis isolates presented in
| Antibiotic(s) | MIC (μg/ml)b distribution (no. of isolates tested) |
|---|---|
| Ampicillin | >16 (19) |
| Amoxicillin/CLA | 4/2 (19) |
| Piperacillin | >64 (19) |
| Cefazolin | >16 (19) |
| Cefotiam | >16 (19) |
| Cefoperazone/SUL | 8/4 (2), 16/8 (14), 32/16 (3) |
| Cefotaxime | >128 (19) |
| Cefotaxime/CLA | ≤0.12/4 (19) |
| Ceftazidime | ≤0.5 (19) |
| Ceftazidime/CLA | ≤0.12/4 (19) |
| Ceftriaxone | >64 (19) |
| Cefpirome | >16 (19) |
| Cefepime | >32 (19) |
| Cefozopran | >16 (19) |
| Cefaclor | >16 (19) |
| Cefpodoxime | >64 (19) |
| Cefoxitin | 4 (10), 8 (8), 32 (1) |
| Cefmetazole | ≤4 (18), 32 (1) |
| Cefotetan | ≤0.5 (19) |
| Flomoxef | ≤1 (17), 2 (2) |
| Imipenem | 2 (19) |
| Meropenem | ≤0.5 (19) |
| Aztreonam | 8 (2), >16 (17) |
| Gentamicin | 2 (4), 8 (1), >8 (14) |
| Amikacin | 4 (5), 8 (14) |
| Minocycline | >8 (19) |
| Levofloxacin | 2 (1), >4 (18) |
| Fosfomycin | >16 (19) |
a
NEG Combo 5J and NEG MIC 5J panels, and ESBL plus Panal were used for MIC determination.